title: Nomifensine maleate in adult attention deficit disorder.
abstract: The authors studied 18 adults (8 men and 10 women) in an open trial of nomifensine maleate for the treatment of attention deficit disorder (ADD). All patients met DSM-III criteria and the Utah criteria for ADD, residual type (RT). Medication effect was measured at week 1 and week 4 of treatment using the Structured Interview for ADD-H Symptoms. Data from week 4 showed that all eight men and seven of the women responded well to nomifensine, showing a significant decrease in ADD with hyperactivity symptoms. Side effects were minimal, consisting of drowsiness, dry mouth, headache, and nausea. One responder (5%) was taken off the medicine after developing an allergic reaction. Results showed that short-term use of nomifensine was relatively free from side effects and was remarkably effective in the treatment of ADD-RT. The authors discussed the implications of the use of nomifensine and related drugs in the treatment of ADD-RT.
authors.affiliation: Division of Mental Retardation and Child Psychiatry, UCLA 90024.
authors.forename: W O
authors.initials: WO
authors.lastname: Shekim
authors.forename: A
authors.initials: A
authors.lastname: Masterson
authors.forename: D P
authors.initials: DP
authors.lastname: Cantwell
authors.forename: G L
authors.initials: GL
authors.lastname: Hanna
authors.forename: J T
authors.initials: JT
authors.lastname: McCracken
mesh_terms: D000293:Adolescent; D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000523:psychology; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007406:Interview, Psychological; D008297:Male; D009627:Nomifensine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D009627:Nomifensine